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Steinbusch LK, Wijnen W, Schwenk RW, Coumans WA,
Hoebers NT, Ouwens DM, Diamant M, Bonen A, Glatz JF,
Luiken JJ. Differential regulation of cardiac glucose and fatty acid
uptake by endosomal pH and actin filaments. Am J Physiol Cell
Physiol 298: C1549 –C1559, 2010. First published April 7, 2010;
doi:10.1152/ajpcell.00334.2009.—Insulin and contraction stimulate
both cardiac glucose and long-chain fatty acid (LCFA) uptake via
translocation of the substrate transporters GLUT4 and CD36, respec-
tively, from intracellular compartments to the sarcolemma. Little is
known about the role of vesicular trafficking elements in insulin- and
contraction-stimulated glucose and LCFA uptake in the heart, espe-
cially whether certain trafficking elements are specifically involved in
GLUT4 versus CD36 translocation. Therefore, we studied the role of
coat proteins, actin- and microtubule-filaments and endosomal pH on
glucose and LCFA uptake into primary cardiomyocytes under basal
conditions and during stimulation with insulin or oligomycin (con-
traction-like AMP-activated protein kinase activator). Inhibition of
coat protein targeting to Golgi/endosomes decreased insulin/oligomy-
cin-stimulated glucose (42%/51%) and LCFA (39%/68%)
uptake. Actin disruption decreased insulin/oligomycin-stimulated glu-
cose uptake (41%/75%), while not affecting LCFA uptake. Mi-
crotubule disruption did not affect substrate uptake under any condi-
tion. Endosomal alkalinization increased basal sarcolemmal CD36
(2-fold), but not GLUT4, content, and concomitantly decreased basal
intracellular membrane GLUT4 and CD36 content (60% and
62%, respectively), indicating successful CD36 translocation and
incomplete GLUT4 translocation. Additionally, endosomal alkaliniza-
tion elevated basal LCFA uptake (1.4-fold) in a nonadditive manner to
insulin/oligomycin, and decreased insulin/oligomycin-stimulated glucose
uptake (32%/68%). In conclusion, 1) CD36 translocation, just like
GLUT4 translocation, is a vesicle-mediated process depending on coat
proteins, and 2) GLUT4 and CD36 trafficking are differentially depen-
dent on endosomal pH and actin filaments. The latter conclusion suggests
novel strategies to alter cardiac substrate preference as part of metabolic
modulation therapy.
cardiac substrate uptake; CD36 translocation; vesicular trafficking;
coat proteins
GLUCOSE AND LONG-CHAIN FATTY ACIDS (LCFA) are the major
fuels for cardiac contractile activity. Glucose transporter-4
(GLUT4) is the major glucose transporter in the heart, and a
number of LCFA transporters have been implicated in cardiac
LCFA uptake, such as CD36 (35), fatty acid transport protein
(FATP)1 (7), and FATP6 (16). To adequately respond to
rapidly varying metabolic demands, the heart is able to acutely
regulate the uptake of both substrates, i.e., via reversible
translocation of GLUT4 and CD36 from intracellular mem-
brane compartments (endosomes) to the sarcolemma (35). In
contrast to CD36, FATP1 and FATP6 do not traffic between
intracellular storage compartments and the sarcolemma in the
heart and have only a minor contribution to basal LCFA uptake
(18, 19). In addition, FATP1 has been shown to translocate to
the cell surface of adipocytes (38), showing that trafficking
processes are tissue specific. The most important physiological
stimuli to induce cardiac GLUT4 and CD36 translocation are
1) a rise in circulating levels of insulin and 2) an increase in
contraction frequency. Hence, the processes of GLUT4 and
CD36 translocation bear close resemblance to each other,
based on their responsiveness to these same physiological
stimuli, and also to various pharmacological stimuli (25).
Additionally, the same signaling enzymes are involved in the
translocation of both transporters. Specifically, phosphatidyl-
inositol 3-kinase and Akt/protein kinase B are involved in
insulin-stimulated translocation of both GLUT4 and CD36,
and AMP-activated protein kinase (AMPK) as well as its
upstream kinase, the tumor suppressor protein LKB1, are
involved in their contraction-stimulated translocation (17).
Whether this similarity between GLUT4 and CD36 transloca-
tion also extends to the subcellular machineries involved in
translocation of each of these transporters remains unexplored.
Because stimulus-induced GLUT4 translocation has been
described since the early 1980s, and stimulus-induced CD36
translocation has only recently begun to be examined, there is
much more information about the subcellular machinery in-
volved in GLUT4 translocation (4, 32) compared with the
CD36 translocation machinery, of which essentially nothing is
known (35). Parts of the subcellular GLUT4 translocation
machinery are formed by 1) coat proteins, involved in pack-
aging of GLUT4 vesicles during their budding from the endo-
somal membranes; 2) cytoskeletal filaments along which the
subcellular GLUT4 vesicles migrate toward the cell surface;
and 3) the recycling endosomes, involved in storage of
GLUT4.
Several coat proteins have been proposed to function in
GLUT4 recycling: caveolin, clathrin, and -COP. Caveolin
(33, 37) and clathrin (2), predominantly plasmalemmal, have
been proposed to play a role in initiation of GLUT4 endocy-
tosis, although this has been disputed by others (31). The
fungal metabolite brefeldin-A is known to interfere with the
retrograde transport from the Golgi apparatus to the endoplas-
mic reticulum through inhibition of coat proteins, e.g., -COP
and Arf1p, involved in formation of transport vesicles resulting
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in impaired sorting from this network (14, 41). Also mistar-
geting of clathrin/adaptor protein complexes might play a role
in this process (23). In addition to the Golgi, the endosomal
compartment, presumably involved in storing GLUT4 and
CD36, also depends on COP proteins and clathrin for its
structural organization, and it will collapse upon brefeldin-A
treatment (45). The use of brefeldin-A in studying insulin-
stimulated GLUT4 translocation in rat adipocytes also yielded
controversial observations: inhibition (22), or no inhibition
(21). Hence, the issue as to which coat proteins are necessary
for regulation of GLUT4 translocation and what their role is in
cardiomyocytes is yet unresolved. To date, brefeldin-A has not
yet been used to investigate the regulation of GLUT4 and
CD36 translocation in the heart.
It is well established that cortical filamentous actin plays a
role in insulin-induced GLUT4 translocation (9, 43). Specifi-
cally, insulin-induced GLUT4 translocation depends on con-
tinuous cycles of actin polymerization/depolymerization, be-
cause both actin stabilizing and destabilizing agents are inhib-
itory to this process (20). Actin structures support ruffling of
the plasma membrane, important for local concentration of
t-SNAREs (42). Controversy exists about the role of the
microtubules in GLUT4 translocation, because microtubule-
disrupting agents have been reported to inhibit insulin-induced
GLUT4 translocation (29) and not to affect this process (1, 36).
None of these filament disruptors have been used to examine
insulin-induced GLUT4 translocation in cardiomyocytes, or
contraction-induced GLUT4 translocation or stimulus-induced
CD36 translocation in any cell type.
One of the key features of endosomes is their acidic interior,
a feature which they share with lysosomes, but not (or, to a
lesser extent) with other organelles (15, 40). Therefore, this
low endosomal pH is thought to be important for endosomal
functioning, as has been established in receptor-mediated en-
docytosis. Endosomal acidification is achieved by the proton-
pumping action of the vesicular-type ATPase (v-ATPase or
V1V0-ATPase), a large multisubunit complex specifically lo-
calized to endosomes and lysosomes (15). On the basis of
pharmacological agents able to disrupt the pH gradient be-
tween endosomes and cytoplasm, as investigated in adipocytes,
skeletal muscle, and heart, the role of endosomal pH in regu-
lation of subcellular GLUT4 localization is controversial. For
example, it has been reported that bafilomycin-A, a specific
inhibitor of the v-ATPase, stimulates (6) or inhibits GLUT4
translocation (8, 46). Furthermore, dissipation of the endoso-
mal/cytoplasmic pH gradient with the proton ionophore mo-
nensin did not affect insulin-induced GLUT4 translocation
(32). However, no studies have yet been undertaken to assess
the role of endosomal functioning in contraction-induced
GLUT4 translocation in the heart. With respect to CD36, the
sole piece of evidence about the role of endosomes in CD36
translocation comes from our earlier work in skeletal muscle,
in which we detected an intracellular membrane fraction en-
riched in CD36 and the transferrin receptor, an established
component of the recycling endosomes (3).
The present study was designed to examine the involvement
of components of the vesicular trafficking machinery, i.e.,
vesicular coat proteins, cytoskeletal filaments, and endosomal
pH, in the regulation of LCFA uptake (through CD36 transloca-
tion), and evaluate the possible similarities and/or differences with
the regulation of glucose uptake (through GLUT4 translocation).
We chose a pharmacological approach to interfere with the func-
tioning of coat proteins (using brefeldin-A), cytoskeletal proteins
(using latrunculin-B and colchicine), and endosomal v-ATPase
(using bafilomycin-A and monensin) rather than a genetic ap-
proach. We chose this approach because 1) brefeldin-A, latrun-
culin-B, colchicine, bafilomycin-A, and monensin are frequently
used established inhibitors; and 2) coat proteins, cytoskeletal
proteins, and endosomal v-ATPase are involved in multiple cru-
cial cellular functions, so that their genetic ablation would seri-
ously hamper cell viability. In contrast to a genetic approach, a
pharmacological approach to block functioning of selected traf-
ficking proteins can be undertaken in a relative short time span
(60 min) without detrimental effects on cell survival.
The involvement of these trafficking components in the
regulation of substrate uptake was studied in regard to insulin
as well as contraction-stimulation. To mimic contraction sig-
naling, we used the F1F0-ATPase inhibitor oligomycin, which,
just like increased muscular work, induces AMPK activation
through an increase of the AMP-to-ATP ratio (25). Given that
different signaling routes appear to be involved in contraction-
induced versus insulin-induced transporter translocation, we
also analyzed whether these differences can be attributed to
vesicular coat proteins, cytoskeletal filaments, or the endoso-
mal pH. For this purpose, it was investigated whether agents
disrupting -COP functioning (brefeldin-A), actin filaments
(latrunculin B), and microtubules (colchicine) or endosomal
pH (monensin and bafilomycin A) were able to alter insulin-
and oligomycin-induced glucose and LCFA uptake.
MATERIALS AND METHODS
Materials. Palmitic acid and [3H]deoxyglucose were obtained from
GE Healthcare (Little Chalfont, UK). [3H]chloroquine was from
Moravek Biochemicals (Brea, CA). Laminin, insulin, oligomycin,
monensin, bafilomycin-A, brefeldin-A, latrunculin-B, and colchicine
were purchased from Sigma (St. Louis, MO). Bovine serum albumin
(BSA) (fraction V), dependent on the application, was derived from
MP Biomedicals (Irvine, CA) (for cell isolation and incubation pur-
poses), or from Sigma (other purposes). Collagenase type II was from
Worthington (Freehold, NJ). CD36 was detected with a monoclonal
antibody (MO25) directed against human CD36, kindly provided by Dr.
N. N. Tandon (Thrombosis and Vascular Biology Laboratory, Otsuka
America Pharmaceutical, Rockville, MD). Rabbit anti-mouse immuno-
globulin horseradish peroxidase and swine anti-rabbit immunoglobulin
horseradish peroxidase were obtained from DAKO (Glostrup, Denmark).
Nonfat dry milk and Western blot reagents were from Bio-Rad (Hercules,
CA) and the enhanced chemiluminescence kit was from Amersham
Pharmacia Biotech (Buckingham, UK). The fluorescently labeled mono-
clonal antibody against the Golgi matrix 130-kDa protein (GM-130) was
from BD Biosciences (San Jose, CA), and the anti--tubulin antibody
was from Iowa Hybridomabank (clone E7) (Iowa City, IA). Texas
red-conjugated phalloidin and DAPI were from Molecular Probes (Eu-
gene, OR), and goat-anti-mouse-TRITC was purchased from DAKO.
Sulfo-N-succinimidyloleate (SSO) is routinely synthesized in our labo-
ratory, as has been previously described (39). Purity of these compounds
was confirmed with infrared spectroscopy (kindly performed by Dr. van
Genderen, Eindhoven Technical University, Eindhoven, the Nether-
lands).
Experimental animals. Male Lewis rats, 200–250 g, were pur-
chased from Charles River Laboratories. All animal procedures were
approved by the Experimental Animal Committee of Maastricht
University, Maastricht, the Netherlands.
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Isolation of cardiomyocytes followed by measurement of substrate
uptake. Cardiomyocytes were isolated from male Lewis rats (200–
250 g) using a Langendorff perfusion system, as previously described
(28). Only when 80% of the cells had a rod-shaped appearance and
excluded Trypan blue were they used for subsequent tracer uptake
studies. Uptake of [1-14C]palmitate (in complex with BSA) and
[3H]deoxyglucose into cardiomyocytes incubated in cell incubation
medium was measured as previously described (28). Substrate uptake
was modulated by insulin and various pharmacological inhibitors (see
figures for exact concentrations and incubation times). All these
inhibitors were dissolved in DMSO, of which the final concentration
in the cell suspensions never exceeded 0.5%. At this concentration,
DMSO did not affect cellular substrate utilization. All agents were added
15–45 min before measurement of substrate uptake at the minimal
concentration at which they exerted the maximal effect. None of these
agents, alone or in combination and including SSO, were found to affect
the percentage of cells that 1) were rod-shaped and 2) excluded Trypan
blue, as parameters of cellular integrity.
Isolation of giant vesicles followed by measurement of substrate
uptake. Giant vesicles were prepared from rat heart, as described
previously (27). Uptake of [9,10-3H]palmitate (in complex with BSA)
and [3H]D-glucose were measured as described previously (27). All
pharmacological inhibitors used were added to giant vesicles 20 min
before determination of palmitate or glucose uptake (see figures for
exact concentrations and incubation times).
[3H]chloroquine uptake assay. Cardiomyocytes (0.5–1.0 mg wet
mass/ml) were preincubated with or without pharmacological agents
similarly as in the substrate uptake assay. At the start of the incuba-
tion, 4 l [3H]chloroquine (250 Ci/ml diluted 1:125 in Milli-Q) were
added. After a 30-min incubation period, 1.5 ml cell suspension was
pulse centrifuged. The supernatant was aspirated, and the lower part
of the cup, containing the cell pellet, was snipped and vortexed in 5 ml
Opti-Fluor (Perkin Elmer, Waltham, MA) until the pellet was com-
pletely dissolved. Samples were counted with a Wallace liquid scin-
tillation counter.
Microscopy. Cells were seeded on laminin-coated coverslips. After
attachment, cells were washed and incubated with the corresponding
inhibitors in cell incubation medium. Cells were fixed with (ice-cold)
methanol, washed for 15 min with 0.2% Triton X-100 in PBS, and
blocked with 2% BSA in PBS. Fluorescent dyes or primary antibodies
[GM-130 (1:100), phalloidin-Texas red (1:100) and -tubulin (1:50)]
were incubated for 1 h at room temperature in PBS with 2% BSA. For
the detection of tubulin, the cells were subsequently washed with PBS
and incubated for 1 h with goat-anti-mouse-tetramethylrhodamine
isothiocyanate (1:100) in PBS with 1% BSA. Cells were washed and
mounted with Glycerol DABCO from Sigma. Nuclei were stained
with DAPI (1:8,000 in PBS). Cells were evaluated with a Zeiss confocal
microscope with a Bio-Rad laser. Image analysis was performed with
ImageJ software (National Institutes of Health, Bethesda, MD).
Surface detection of CD36. Directly after isolation, cell suspen-
sions of cardiomyocytes (100,000 cells/well) were plated in laminin-
coated (20 g/ml) 35-mm culture plates and were allowed to attach to
the plates for 1 h. Afterward, the cells were incubated with 0.35%
DMSO or with the pharmacological agents as described for the
substrate uptake assay. As previously described (44), cells were
biotinylated with the cell membrane-impermeable reagent sulfo-NHS-
LC-biotin in bicarbonate medium at a final concentration of 1 mg/ml
for 45 min at 4°C while shaking. The reaction was quenched with
ice-cold glycine in bicarbonate medium (100 mM). After a brief wash
with ice-cold bicarbonate medium, cells were lysed by scraping in 250
l lysis buffer. Lysates were incubated at 4°C for 1 h while rotating
and were centrifuged for 10 min at 13,000 g at 4°C. Supernatant (15
l) was used as total lysate sample, and 200 l supernatant was
incubated overnight with streptavidin beads. Samples were briefly
centrifuged, and beads were washed twice with lysis buffer. Biotin-
ylated proteins were eluted by incubation of the streptavidin beads for
5 min at 95°C in sample buffer. Samples were subjected to SDS-
polyacrylamide gel electrophoresis, followed by Western blotting, as
previously described (25).
Cellular fractionation of rat cardiomyocytes. Freshly isolated car-
diomyocytes were incubated with oligomycin or trafficking inhibitors
similarly to the substrate uptake experiments. Subsequently, cell
suspensions were processed according to the fractionation procedure
as previously described (26).
Other procedures. Cellular wet mass was obtained from cell
samples taken during the incubation period and determined after
centrifugation for 2–3 s at maximal speed in a microcentrifuge and
subsequent removal of the supernatant. Protein was quantified with
the bicinchoninic acid protein assay (Pierce, Rockford, IL) according
to manufacturer’s instructions.
Data presentation and statistical analysis. All data are presented as
means  SE for the indicated number of myocyte preparations.
Statistical difference between groups of observations was evaluated
by ANOVA or Student’s t-test. P  0.05 was considered significant.
RESULTS
Verification of the disrupting actions of brefeldin-A, latruncu-
lin-B, and colchicine at the ultrastructural level in cardiomyocytes.
One of the reported cellular effects of brefeldin-A treatment is
fragmentation of the Golgi apparatus (13). To evaluate the
effectiveness of brefeldin-A on Golgi disruption in cardiomy-
ocytes, cells were treated, fixed, and stained for Golgi marker
130, a Golgi-localized protein. The Golgi apparatus was de-
tectable as an elongated structure stretching from the vicinity
of the nucleus through the sarcoplasmic reticulum, parallel
along the contractile fibers (Fig. 1A). With brefeldin-A, this
staining became less intense and more dispersed. The lack of
high-intensity staining after brefeldin-A treatment indicates
that the Golgi apparatus, and likely also the endosomes, have
been fragmented (Fig. 1A).
Latrunculin-B has been used as an inhibitor of actin poly-
merization and thereby as a destabilizing agent for actin fila-
ments (20). Treatment with latrunculin-B was evaluated by
actin staining with phalloidin-Texas red. The striated actin
pattern, a characteristic feature of cardiomyocytes, was mark-
edly less pronounced and more dispersed upon treatment with
20 M latrunculin-B (Fig. 1B). In addition, black holes ap-
peared between the actin striations of latrunculin-B-treated
cardiomyocytes, indicating that the actin cytoskeleton has
ruptured at several intracellular locations. Finally, cell mor-
phology altered from rod-shaped with rectangular ends to a
shorter and rounder appearance (Fig. 1B). Hence, the subcel-
lular actin network was damaged by latrunculin-B treatment.
Colchicine is a disruptor of the microtubule network (1).
Optimal concentrations were established using immunofluo-
rescence staining of control and colchicine-treated cardiomy-
ocytes. Incubation of cardiomyocytes for 1 h in the presence of
1 M colchicine induced structural changes in the microtubule
network. The perinuclear staining became less prominent and
the overall organization of the microtubules was disrupted, as
indicated by a more diffuse staining pattern in treated cells
(Fig. 1C). Another well-established colchicine-induced change
in cell morphology is the loss of cell shape (34). Clearly,
colchicine treatment of cardiomyocytes caused a metamorpho-
sis from the characteristic rod-shaped appearance into a more
spread-out, less-defined cell shape.
Taken together, we could verify the effectiveness of brefel-
din-A, latrunculin-B, and colchicine in cardiomyocytes.
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Verification of alkalizing action of monensin and bafilomy-
cin-A in cardiomyocytes. Intracellular accumulation of divalent
weak bases, such as chloroquine, is a sensitive pH indicator of
the interior of acidic organelles (12). In nontreated cardiomy-
ocytes, the chloroquine accumulation factor was 133  22-
fold, which was not influenced by addition of insulin, oligo-
mycin, brefeldin-A, latrunculin-B, or colchicine (Fig. 1D). In
contrast, elevation of the endosomal pH by monensin or
bafilomycin-A markedly decreased chloroquine accumulation
(Fig. 1D). Hence, monensin and bafilomycin-A effectively
interfere with endosomal functioning via alkalinization of the
acidic lumen.
Excluding direct effects of trafficking-inhibiting agents on
GLUT4 and CD36. The possibility exists that the used traf-
ficking inhibitors would affect glucose or LCFA uptake into
cardiomyocytes through direct interaction with GLUT4 or
CD36 at the plasma membrane. We investigated this option by
preparation of giant vesicles which solely consist of sarcolem-
mal membranes encapsulating soluble cytoplasm. Intracellular
organelles such as the endosomal recycling compartment are
absent (27), so that translocation of transporters cannot occur.
Hence, during incubation of giant vesicles with selected stim-
uli, the amount of GLUT4 and CD36 present at the vesicular
membrane remains fixed, and therefore alterations in transport
rates can only be due to changes in the activities of these
substrate transporters. We observed that none of the used
trafficking inhibitors altered the uptake rates of glucose and
LCFA into giant vesicles (Fig. 2), indicating that any inhibitory
effect of these agents on regulation of substrate uptake into
cardiomyocytes cannot be ascribed to a direct inhibition of
sarcolemmal GLUT4 or CD36.
Excluding nonspecific effects of trafficking-inhibiting agents
on insulin and AMPK signaling. To demonstrate that the
cytoskeleton disruptors, brefeldin-A and latrunculin-B, did not
interfere with oligomycin-induced AMPK activation, we eval-
uated Ser79 phosphorylation of the AMPK substrate acetyl-CoA
carboxylase (ACC) by Western blotting (Fig. 3A). Symmetrically,
we determined insulin-induced Akt-Ser473 phosphorylation (Fig.
3B). Insulin and oligomycin enhanced phosphorylation of Akt and
ACC, respectively, by 10-fold (Fig. 3), in agreement with earlier
observations in cardiomyocytes (23, 28). However, none of the
used trafficking inhibitors were observed to alter the phosphory-
lation states of these markers of insulin and AMPK signaling (Fig.
3). Hence, any effects of these agents on regulation of substrate
uptake into cardiomyocytes cannot be attributed to nonspecific
effects of these compounds on insulin and AMPK signaling.
Effects of trafficking-inhibiting agents on substrate uptake
into cardiomyocytes. Insulin and oligomycin were used to
stimulate cardiac substrate uptake. As displayed in Fig. 4,
insulin and oligomycin treatment increased glucose uptake by
5- to 12-fold and 1.7- to 2.5-fold, respectively, and LCFA
uptake by 1.3- to 1.5-fold and 1.7- to 2.0-fold, respectively, in
Fig. 1. Effect of trafficking inhibitors on cardiomyocyte morphology and endosomal function. A: cardiomyocyte suspensions were incubated without or with 20
g/ml brefeldin-A (45 min) before fixation and Golgi staining with GM-130. B: cardiomyocyte suspensions were incubated without or with 20 g/ml
latrunculin-B (45 min) before fixation and actin staining with phalloidin Texas red. C: cardiomyocyte suspensions were incubated without or with 1 M
colchicine (45 min) before fixation and staining of microtubules with -tubulin. D: cardiomyocyte suspensions were incubated without or with 100 nM insulin
(20 min), 5 M oligomycin (20 min), 20 g/ml brefeldin-A (45 min), 20 g/ml latrunculin-B (45 min), 1 M colchicine (45 min), 100 nM monensin (25 min),
or 100 nM bafilomycin-A (25 min) at the time periods indicated before incubation (30 min) with trace amounts of [3H]chloroquine for assessment of endosomal
function. Data are means  SE of 4–6 experiments carried out with different cardiomyocyte preparations. *Significantly different from cardiomyocytes without
additions (P  0.05). C, control; Ins, insulin; Oli, oligomycin; BFA, brefeldin-A; LcB, latrunculin-B; Col, colchicine; Mon, monensin; Baf, bafilomycin-A.
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agreement with our earlier observations (25, 26). Brefeldin-A
treatment did not alter basal glucose and LCFA uptake but
markedly inhibited insulin-stimulated glucose uptake (42%),
oligomycin-stimulated glucose uptake (51%), and oligomy-
cin-stimulated LCFA uptake (39%) and largely inhibited
insulin-stimulated LCFA uptake (68%; Fig. 4A). Latruncu-
lin-B treatment did not alter basal glucose uptake and also did
not alter LCFA uptake, neither under basal nor upon treatment
of cardiomyocytes with insulin or oligomycin (Fig. 4B). In
contrast, this actin filament-disrupting agent markedly inhib-
ited insulin-stimulated glucose uptake (41%) and largely
inhibited oligomycin-stimulated glucose uptake (75%; Fig.
4B). Colchicine treatment neither influenced basal glucose and
LCFA uptake nor insulin- or oligomycin-stimulated glucose
and LCFA uptake (Fig. 4C). Monensin and bafilomycin-A
exerted very similar effects on substrate uptake into cardiomy-
ocytes, bolstering the notion that these agents act via the same
mechanism, i.e., disruption of low endosomal pH. Specifically,
monensin or bafilomycin-A did not alter basal glucose uptake,
while simultaneously increasing basal LCFA uptake by 1.3-
and 1.4-fold, respectively. Furthermore, monensin and bafilo-
mycin-A markedly inhibited insulin-stimulated glucose uptake
(32% and 52%, respectively) and largely inhibited oligo-
mycin-stimulated glucose uptake (49% and 68%, respec-
tively), but these agents had no effect on insulin- or oligomy-
cin-stimulated LCFA uptake (Fig. 4D).
When combining the results obtained with all applied traf-
ficking inhibitors, we conclude that insulin/oligomycin-stimu-
lated glucose and LCFA uptake resemble each other in their
similar dependence on coat protein-mediated vesicle formation
and their independence of microtubules. In contrast, the endo-
somal pH is differentially involved in basal and insulin/oligo-
mycin-stimulated glucose and LCFA uptake. Moreover, insu-
lin/oligomycin-stimulated glucose uptake, but not LCFA up-
take, is dependent on actin filaments.
Involvement of CD36 in alterations seen in cardiomyocytes
treated with alkalizing agents. We observed an increase in
basal LCFA uptake in cardiomyocytes treated with alkalizing
agents. To establish whether CD36 was involved in this pro-
cess, we applied the specific CD36 inhibitor SSO (11, 18). In
agreement with earlier studies (26), SSO pretreatment partially
inhibited LCFA uptake into nonstimulated cardiomyocytes (con-
trol; 30%) (Fig. 5A). Furthermore, SSO completely reduced the
increase in basal LCFA uptake in monensin- and bafilomycin-A-
treated cells, i.e., to the same residual level as observed for
nonstimulated cardiomyocytes (Fig. 5A). This indicates that
Fig. 2. Effects of trafficking inhibitors on intrinsic activity of substrate transporters in heart-derived giant vesicles. Giant vesicle suspensions were incubated
without or with 20 g/ml brefeldin-A, 20 g/ml latrunculin-B, 1 M colchicine, 100 nM monensin, or 100 nM bafilomycin-A before execution of glucose uptake
studies (2 min) or palmitate uptake studies (15 s). Data are means  SE of 3–4 experiments carried out with different cardiomyocyte preparations.
Fig. 3. Effect of trafficking inhibitors on phosphory-
lation of signaling proteins in insulin and AMP-acti-
vated protein kinase (contraction) signaling. Cardiomy-
ocyte suspensions were preincubated without or with 20
g/ml brefeldin-A (45 min), 20 g/ml latrunculin-B (45
min), 1 M colchicine (45 min), 100 nM monensin (25
min), or 100 nM bafilomycin-A (25 min) at the time
periods indicated and were subsequently incubated with
or without 100 nM insulin or 5 M oligomycin for 15
min. Subsequently, samples were processed for detec-
tion of phospho-Ser79-acetyl-CoA carboxylase (ACC)
and phospho-Ser473-Akt by Western blotting.
C1553TRAFFICKING AND CARDIAC SUBSTRATE UPTAKE
AJP-Cell Physiol • VOL 298 • JUNE 2010 • www.ajpcell.org
Downloaded from journals.physiology.org/journal/ajpcell at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
CD36 is necessary for the action of these endosomal pH-
elevating agents on LCFA uptake into cardiomyocytes. SSO
treatment did not affect glucose uptake into cardiomyocytes,
confirming the specificity of this compound for CD36 (Fig.
5A). Additionally, none of the trafficking inhibitors decreased
cardiomyocyte glucose uptake in either the absence or the
presence of SSO (Fig. 5A).
The involvement of CD36 in the increased basal LCFA
uptake in monensin- and bafilomycin-A-treated cardiomyo-
cytes suggests that both endosomal inhibitors induce CD36
translocation to the sarcolemma. To verify this, surface protein
biotinylation was performed, allowing quantification of CD36-
translocation to the cell surface. We found the amount of CD36
in the biotin-labeled fraction to be increased in insulin-treated
(3.7-fold) or oligomycin-treated (4.0-fold) cardiomyocytes
compared with nonstimulated cells (Fig. 5, B and D). This
confirmed earlier observations using this procedure in insulin-
and oligomycin-stimulated Chinese hamster ovary cells (44),
and the suitability of this procedure to quantify the cell surface
presence of recycling proteins. An increase in CD36 cell
surface content was also observed upon treatment of cardio-
myocytes with monensin (2.5-fold) or bafilomycin-A (2.0-
fold), whereas no alterations were seen in GLUT4 surface
presence (Fig. 5, C and D). To assess whether the increase in
sarcolemmal CD36 in monensin or bafilomycin-A treated car-
diomyocytes was due to translocation from intracellular mem-
brane compartments, subcellular fractionation was performed.
First of all, this method confirmed the biotinylation experi-
ments; the presence of CD36 in the sarcolemmal fraction was
found to be increased upon cardiomyocyte treatment with
monensin (1.3-fold) or bafilomycin-A (1.2-fold), but not upon
brefeldin-A, latrunculin-B, or colchicine treatment (Fig. 6).
Fig. 4. Effects of trafficking inhibitors on glucose
and light-chain fatty acid (LCFA) uptake into car-
diomyocytes. Cardiomyocyte suspensions were pre-
incubated without or with 20 g/ml brefeldin-A (45
min) (A), 20 g/ml latrunculin-B (45 min) (B), 1
M colchicine (45 min) (C), or 100 nM monensin
(25 min) or 100 nM bafilomycin-A (25 min) (D) at
the time periods indicated and were subsequently
incubated with or without 100 nM insulin or 5 M
oligomycin for 15 min before execution of palmitate
uptake studies (3 min) or deoxyglucose uptake stud-
ies (3 min). Data are means  SE of 4–12 experi-
ments carried out with different cardiomyocyte
preparations. *Significantly different from cardio-
myocytes stimulated with insulin or oligomycin in
the absence of trafficking inhibitors (P  0.05);
^significantly different from cardiomyocytes with-
out trafficking inhibitor (P  0.05).
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Fig. 5. Involvement of CD36 in increased basal LCFA uptake into cardiomyocytes after monensin/bafilomycin-A treatment. A: modulation of the stimulatory
effects of trafficking inhibitors on LCFA uptake by sulfo-N-succinimidyloleate (SSO). Cell suspensions were preincubated with DMSO (basal) or with 500 M
SSO (dissolved in DMSO), after which the cells were washed twice, as described in MATERIALS AND METHODS. Subsequently, cells were incubated with or without
100 nM monensin (25 min), 100 nM bafilomycin-A (25 min), 20 g/ml brefeldin-A (45 min), 20 g/ml latrunculin-B (45 min), or 1 M colchicines (45 min)
before execution of palmitate uptake studies (3 min) or deoxyglucose uptake studies (3 min). Data are means  SE of 3–4 experiments carried out with different
cardiomyocyte preparations. *Significantly different from cardiomyocytes without SSO (P  0.05); ^significantly different from cardiomyocytes without
inhibitor (P  0.05). B–D: effect of trafficking inhibitors on CD36 surface presence: seeded cells were incubated with DMSO (control), 100 nM insulin (20 min),
5 M oligomycin (20 min), 100 nM monensin (25 min), or 100 nM bafilomycin-A (25 min) before biotinylation and cell lysis. CD36 and glucose transporter-4
(GLUT4) were detected by Western blotting before biotinylation (total) and after biotinylation (surface). Values are relative to control presence of CD36 at the
sarcolemma. Data are means  SE of 3–4 experiments carried out with different cardiomyocyte preparations. Representative Western blots are displayed.
*Significantly different from myocytes without additions (P  0.05).
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Importantly, the intracellular membrane content of CD36 was
found to be decreased by monensin (62%), bafilomycin-A
(58%) or latrunculin-B (55%) treatment, but not by brefel-
din-A or colchicine (Fig. 6). This indicates that dissipation of
endosomal pH, but not disruption of assembly of coat proteins,
actin filaments or microtubule, causes CD36 translocation from
intracellular stores to the sarcolemma. In these same subcellu-
lar fractions we measured the content of the major cardiac
glucose transporter GLUT4, which was not altered by any of
the applied trafficking inhibitors, in agreement with the lack of
an effect of monensin or bafilomycin-A on cell surface GLUT4
content, and in agreement with the lack of an effect of these
inhibitors on basal glucose uptake. However, we found mo-
nensin (60%) or bafilomycin-A (42%) to reduce the
GLUT4 content in the intracellular membrane fraction, i.e.,
whereas brefeldin-A, latrunculin-B, or colchicines were unsuc-
cessful in this respect. Hence, it seems that monensin and
bafilomycin induced an incomplete GLUT4 translocation
event. In these subcellular fractionation experiments, oligomy-
cin was used as positive control for CD36 and GLUT4 trans-
location. Oligomycin treatment was observed to increase sar-
colemmal CD36 (1.2-fold) and GLUT4 (1.5-fold) content and
to decrease intracellular CD36 (61%) and GLUT4 (77%)
content, confirming earlier data (25) and indicating the suit-
ability of the subcellular fractionation method.
DISCUSSION
Translocation of both GLUT4 and CD36 are pivotal pro-
cesses by which the heart regulates its substrate uptake. To
modulate cardiac substrate preference, e.g., to favor glucose
over LCFA utilization, it would be of interest to identify
subcellular components specifically involved in the transloca-
tion of either GLUT4 or of CD36. However, the signal trans-
duction cascades, as far as these have been investigated,
appear not to discriminate between translocation of GLUT4
and that of CD36 in cardiomyocytes (see Introduction and
also Ref. 35).
In the present study, we have extended the comparison
between the translocation of GLUT4 and that of CD36 in
cardiomyocytes by investigating the possible similarities and
differences in the reliance on trafficking structures. We applied
compounds that disrupt selected components of the subcellular
trafficking machinery and have come to the following conclu-
sions. 1) Glucose uptake and LCFA uptake, stimulated by
either insulin or oligomycin, show similar dependence on coat
proteins. 2) Actin filaments do not play a role in LCFA uptake
but are involved in glucose uptake stimulated by insulin or
oligomycin, whereas microtubules are neither involved in in-
sulin/oligomycin-stimulated glucose uptake nor in insulin/oli-
gomycin-stimulated LCFA uptake. 3) Proper endosomal pro-
ton pumping is necessary for insulin/oligomycin-stimulated
glucose uptake as well as for maintaining low basal LCFA
uptake rates and intracellular retention of CD36.
Taken together, we have identified trafficking elements that
are 1) similarly involved in the regulation of glucose and
LCFA uptake (coat proteins), 2) not involved in the regulation
of uptake of both substrates (microtubules), and 3) differen-
Fig. 6. Effect of trafficking inhibitors on subcellular localization of GLUT4 and CD36. A: cardiomyocyte suspensions were incubated without or with 5 M
oligomycin (15 min), 20 g/ml brefeldin-A (45 min), 20 g/ml latrunculin-B (45 min), 1 M colchicine (45 min), 100 nM monensin (25 min), or 100 nM
bafilomycin-A (25 min). Cells were processed for fractionation and later detection of GLUT4 and CD36 by Western blotting. Data are means  SE of 3–4
experiments carried out with different cardiomyocyte preparations. Representative Western blots are displayed. Lines indicate that samples were loaded on
different blots. B: graphs show quantification and analysis of 3-4 Western blots. *Significantly different from myocytes without additions (P  0.05). LDM,
low-density microsomal fraction; PM, plasmalemmal fraction.
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tially involved in the regulation of glucose uptake versus
LCFA uptake (actin filaments and endosomal pH).
Involvement of coat proteins in regulation of substrate
uptake into cardiomyocytes. This is the first study that has used
brefeldin-A to investigate the role of coat proteins in the
regulation of cardiac substrate uptake. Under our experimental
conditions, brefeldin-A treatment resulted in the disruption of
Golgi structures, confirming that this fungal inhibitor indeed
affected coat protein-mediated processes in cardiomyocytes.
Brefeldin-A did not alter basal glucose or LCFA uptake in
cardiomyocytes, nor did it alter the subcellular localization of
GLUT4 and CD36. This indicates that coat proteins are not
involved in the maintenance of a low surface content of
GLUT4 and CD36 in nonstimulated cardiomyocytes.
In contrast, brefeldin-A inhibited, at least partially, both
insulin- and oligomycin-stimulated glucose uptake and insulin-
and oligomycin-stimulated LCFA uptake. Hence, coat proteins
are involved in stimulation of glucose and LCFA uptake upon
insulin or oligomycin treatment of cardiomyocytes. Because
brefeldin-A inhibits both COP and clathrin targeting to Golgi/
endosomal membranes, it cannot be discriminated whether
malfunctioning of -COP versus clathrin is responsible for
brefeldin-A-induced inhibition of insulin/oligomycin-stimu-
lated glucose and LCFA uptake. Notwithstanding, the inhibi-
tion of stimulus-induced LCFA uptake by brefeldin-A provides
the first evidence that CD36 translocation is a vesicle-mediated
process dependent on coat proteins, just like GLUT4 translo-
cation.
Involvement of cytoskeletal elements in regulation of sub-
strate uptake into cardiomyocytes. Like brefeldin-A, inhibitors
of actin filaments such as cytochalasin-D or latrunculin-B,
have not been used in the context of cardiac substrate uptake.
We were able to confirm that latrunculin-B effectively disrupts
the actin network in cardiomyocytes, indicating that this drug
is suitable to study the involvement of the actin filaments in
subcellular processes. Latrunculin-B did not affect basal glu-
cose or LCFA uptake, nor did it alter basal presence of CD36
and GLUT4 at the sarcolemma, and the basal presence of
GLUT4 in the intracellular compartments. Surprisingly, latrun-
culin-B decreased the basal presence of CD36 in the intracel-
lular compartments, indicating that disruption of actin poly-
merization dynamics results in an initiation of CD36 translo-
cation but not in completion of this process. The functional
relevance of this failing CD36 translocation is presently in-
completely understood.
More interestingly, latrunculin-B markedly inhibited insu-
lin-stimulated glucose uptake and completely inhibited oligo-
mycin-stimulated glucose uptake. The inhibition of insulin-
stimulated glucose uptake is regarded as a classical latruncu-
lin-B action in adipocytes as a result of actin filament
disruption (24) and confirms the effectiveness of this drug in
cardiomyocytes. In contrast, the inhibition of AMPK-mediated
glucose uptake by latrunculin-B and the lack of an effect of
latrunculin-B on basal or insulin/oligomycin-stimulated LCFA
uptake are novel observations. This suggests that actin fila-
ments are specifically involved in stimulus-induced GLUT4
translocation and not in CD36 translocation.
Conversely, we found that colchicine, while successfully
disrupting the microtubule network in cardiomyocytes, had no
effect on subcellular GLUT4 and CD36 distribution and on
glucose and LCFA uptake into cardiomyocytes under any
condition. This indicates that, at least in the heart, this fila-
mentous network does not provide the scaffolding system
along which the intracellular GLUT4 and CD36 vesicles recy-
cle between the endosomal compartment and the cell surface.
In conclusion, this is the first study to identify a subcellular
component, i.e., actin filaments, involved in selective translo-
cation of one of the transporters, and to provide evidence that
GLUT4 translocation and CD36 translocation are separate
events. Combined with the brefeldin-A data, it appears that the
processes of GLUT4 translocation and CD36 translocation
depend on mutually shared trafficking structures, as well as on
structures specifically dedicated to the translocation of either
one of these substrate transporters.
Involvement of endosomal functioning in regulation of sub-
strate uptake into cardiomyocytes. The role of the endosomal
pH in translocation processes such as that of GLUT4, as
investigated in adipocytes and skeletal muscle, is controversial
(see Introduction). We used two structurally unrelated agents
with different action modes to compare the role of endosomal
pH in the regulation of glucose and LCFA uptake in cardio-
myocytes. Monensin and bafilomycin-A both blocked intracel-
lular accumulation of the divalent weak base chloroquine in
cardiomyocytes, which confirms their dissipating effect on
endosomal proton trapping. The other trafficking inhibitors
used had no effect on chloroquine accumulation, indicating
that there are no nonspecific effects of these compounds on the
endosomal pH.
Our observations on the effects of both endosomal inhibitors
on substrate uptake into cardiac myocytes revealed that endo-
somal pH plays an entirely different role in subcellular distri-
bution of GLUT4 than of CD36. Namely, we observed that
both inhibitors markedly increased basal LCFA uptake without
altering basal glucose uptake. In agreement with this, two
independent techniques for measurement of cell surface con-
tent of proteins show that both endosomal inhibitors increase
the sarcolemmal content of CD36, but not that of GLUT4 (Fig.
5, C and D, and Fig. 6). These results suggest that monensin/
bafilomycin-A-induced LCFA uptake is due to CD36 translo-
cation, and that the lack of an effect of monensin and bafilo-
mycin-A is due to a lack of an effect on GLUT4 translocation.
Definite evidence that the selective action of monensin/bafilo-
mycin-A on LCFA uptake is mediated via CD36 translocation
from intracellular stores to the sarcolemma was provided by
the sensitivity of monensin/bafilomycin-enhanced LCFA up-
take to inhibition by SSO. Surprisingly, monensin and bafilo-
mycin-A reduced the GLUT4 content within the intracellular
membrane fraction, suggesting that both alkalizing agents
similarly induced the budding of GLUT4 and of CD36 vesicles
from the endosomal compartment. However, only the CD36-
containing vesicles are able to reach the cell surface upon
endosomal alkalinization.
A possible explanation for the role of endosomal alkaliniza-
tion in budding of GLUT4 and CD36 vesicles from the endo-
somal membranes could include that one of the endosomal
proteins regulating this budding process is repressed by low
pH, and becomes deinhibited by a dissipation of the pH
gradient. Furthermore, our results suggest that CD36-contain-
ing vesicles would travel directly to the sarcolemma upon
budding from endosomal membranes, whereas GLUT4-con-
taining vesicles might travel to the sarcolemma via a hypothet-
ical endosomal GLUT4 transit compartment, in which GLUT4
C1557TRAFFICKING AND CARDIAC SUBSTRATE UPTAKE
AJP-Cell Physiol • VOL 298 • JUNE 2010 • www.ajpcell.org
Downloaded from journals.physiology.org/journal/ajpcell at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
would be unpacked and subsequently reloaded into different
transport vesicles for further transport to the sarcolemma.
However, in this intermediary station the proteins that regulate
vesicle budding might be repressed by endosomal alkaliniza-
tion, instead of activated in case of those in the original
endosomal GLUT4 stores. Then, GLUT4 arriving in this com-
partment upon cardiomyocyte treatment with endosomal alka-
linizing agents would get stuck here.
Remarkably, this subcellular distribution of both substrate
transporters, with CD36 being at the cell surface and GLUT4
intracellular during endosomal alkalinization, resembles that of
the early insulin-resistant heart, as observed in young adult
obese Zucker rats (10) and in rats fed a high-fat diet for 10 wk
(30). This suggests that endosomal alkalinization in the early
insulin-resistant heart could result in selective cell surface
accumulation of CD36 and hence might contribute to the
development of insulin resistance through increased intramyo-
cellular LCFA accumulation. The loss of the endosomal to
cytoplasmic pH gradient might possibly be due to a reduced
energy reserve associated with mitochondrial dysfunction dur-
ing insulin resistance (5). The remaining ATP produced would
then only be used for the most necessary cellular processes,
and less ATP would be made available for proton pumping into
the endosomal compartment.
Another striking difference about the role of the endosomal
pH in the regulation of glucose versus LCFA uptake is that
insulin/oligomycin-stimulated glucose uptake was partially
blocked by monensin/bafilomycin-A treatment, while these
compounds had no effect on insulin/oligomycin-stimulated
LCFA uptake. The lack of an effect of monensin/bafilomy-
cin-A on insulin/oligomycin-stimulated LCFA uptake must be
appreciated in view of their stimulatory action on basal LCFA
uptake: namely, the effects of monensin/bafilomycin-A on one
hand and insulin/oligomycin on the other were nonadditive.
Importantly, this nonadditivity is regarded as kinetic evidence
that all these factors use a common molecular mechanism to
increase LCFA uptake. Because insulin and oligomycin them-
selves do not or only slightly alkalinize the endosomes (Fig.
1D), the effects of insulin and oligomycin on translocation
must be downstream of the alkalinization process. Hence,
insulin/oligomycin treatment might activate the same budding
protein as endosomal alkalinization does, but then via phos-
phorylation.
The blockade of insulin/oligomycin-stimulated glucose up-
take treatment of cardiomyocytes with endosomal alkalinizing
agents is in agreement with earlier studies on insulin-stimu-
lated GLUT4 translocation and glucose uptake in adipocytes
(8) and cardiomyocytes (46). Perhaps, the hypothetical GLUT4
transit compartment with budding proteins inhibited by a rise
in pH might offer an explanation not only for the incomplete
GLUT4 translocation, but also for the inhibition of insulin/
oligomycin-induced GLUT4 translocation upon endosomal al-
kalinization. Namely, GLUT4 induced to translocate from the
endosomal GLUT4 stores upon insulin/oligomycin treatment
would not be further processed in this transit compartment
when the pH gradient between this compartment and the
cytoplasm has been dissipated by alkalinizing agents.
Nonetheless and irrespective of the provided possible expla-
nations, it is clear that the endosomal pH plays a differential
role in the regulation of cardiac glucose and LCFA uptake.
Concluding remarks. The ability of brefeldin-A to inhibit
insulin- or oligomycin-stimulated LCFA uptake provides the
first evidence for the vesicle-dependent nature of CD36 trans-
location upon stimulation of cardiomyocytes with hormonal
and pharmacological stimuli. This demonstrates that the simi-
larity in the regulation of translocation of GLUT4 and CD36
extends beyond the signaling pathways (as reviewed in Ref.
35) to the vesicular trafficking machinery. However, actin
filaments are solely involved in GLUT4 recycling, and the
endosomal proton pump has differential roles in GLUT4 and
CD36 recycling. With the actin filaments being specifically
involved in GLUT4 recycling, it might be speculated that there
is also a filamentous network entirely dedicated to CD36
recycling. However, such a candidate filament network is not
provided by the microtubules.
Finally, the differential involvement of the endosomal pro-
ton pump and actin filaments in the regulation of GLUT4 and
CD36 distribution in cardiomyocytes provides novel therapeu-
tic strategies to alter substrate preference in metabolic disease.
For instance, pharmacological inhibitors that are specifically
targeted to the heart to disturb vesicle traffic along actin
filaments (for inhibition of glucose uptake) could theoretically
be used as therapeutic agents to correct substrate preference in
the hypertrophied heart, which is characterized by excess
glucose utilization. Conversely, in metabolic diseases such as
type-2 diabetes, cardiospecific pharmacological agents that
stimulate v-ATPase activity would lower LCFA uptake in the
lipid-overloaded heart and may thereby restore insulin-stimu-
lated glucose uptake and prevent or reverse the development of
metabolic cardiomyopathy.
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